Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop.
Watt KD, Burak K, Deschênes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner EL, Yoshida EM; Canadian Transplant Hepatology Outcomes Research Network. Watt KD, et al. Among authors: lilly l. Can J Gastroenterol. 2006 Nov;20(11):725-34. doi: 10.1155/2006/238218. Can J Gastroenterol. 2006. PMID: 17111055 Free PMC article. Review.
Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up.
Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, Bain V, Ghent C, Marotta P, Grant D, Wall W, Tchervenkov J, Barkun J, Roy A, Marleau D, McAlister V, Peltekian K. Greig P, et al. Among authors: lilly l. Liver Transpl. 2003 Jun;9(6):587-95. doi: 10.1053/jlts.2003.50102. Liver Transpl. 2003. PMID: 12783400 Free article. Clinical Trial.
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus.
Chatur N, Ramji A, Bain VG, Ma MM, Marotta PJ, Ghent CN, Lilly LB, Heathcote EJ, Deschenes M, Lee SS, Steinbrecher UP, Yoshida EM. Chatur N, et al. Liver Int. 2005 Aug;25(4):723-7. doi: 10.1111/j.1478-3231.2005.01107.x. Liver Int. 2005. PMID: 15998421 Clinical Trial.
Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, Bain VG, Wall WJ, Roy A, Balshaw RF, Barkun JS. Yoshida EM, et al. Liver Transpl. 2005 Sep;11(9):1064-72. doi: 10.1002/lt.20490. Liver Transpl. 2005. PMID: 16123958 Free article. Clinical Trial.
The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age.
Selzner N, Girgrah N, Lilly L, Guindi M, Selzner M, Therapondos G, Adeyi O, McGilvray I, Cattral M, Greig PD, Grant D, Levy G, Renner EL. Selzner N, et al. Among authors: lilly l. Liver Transpl. 2008 Dec;14(12):1778-86. doi: 10.1002/lt.21598. Liver Transpl. 2008. PMID: 19025914 Free article.
216 results